pembrolizumab
merck
['keynote 412', 'pembro']
 results of the ph3 study keynote 412: no benefit in efs nor os from adding pembrolizumab to crt in la-hnscc patients nor in itt or pdl1 positive subgroups. time to rethink io-rt combinations strategies #esmo2022 #oncoalert 